(AOF) – Moderna is in sharp decline after lowering its annual outlook. Victim of the lull on the Covid-19 front, the pharmaceutical laboratory (-8.32% to $69.86) is only expecting sales of “at least $6 billion” for 2023 compared to “between 6 and 8 billion” previously. It posted an adjusted loss per share of $9.53 for the quarter and $12.89 for nine months. Another laboratory that has benefited greatly from the Covid-19 pandemic, Pfizer published its first quarterly loss since 2019 on Tuesday, with a loss per share adjusted to $0.17.
The other big winner from Covid, Pfizer revealed a net loss of $2.38 billion in the third quarter in published data compared to a profit of $8.6 billion a year earlier. Same cause, same consequence, the fall in sales of its Covid-19 products (Paxlovid and Comirnaty) caused a 41% drop in its turnover to $13.23 billion.
Stéphane Bancel, president and CEO of Moderna, however, wants to remain optimistic. “During this quarter, we demonstrated our ability to increase our share of the US market and we now expect this year’s vaccination rate to be similar to last fall,” he said. declared. “In the third quarter, we significantly scaled our manufacturing infrastructure to make our Covid-19 franchise profitable for 2024 and beyond.” Moderna forecasts 2024 sales of around $4 billion, a return to growth in 2025 and reaching balance in 2026.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
